[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657881":3},{"organization":4,"outcomesModule":7,"designInfo":99,"detailedDescription":11,"studyPopulation":11,"armGroups":110,"interventions":121,"overallOfficials":11,"centralContacts":132,"locations":140,"responsibleParty":175,"collaborators":177,"id":180,"slug":181,"hasResults":182,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":182,"sex":188,"minAge":189,"maxAge":11,"enrollmentInfo":190,"targetDuration":11,"studyType":193,"phases":194,"briefSummary":196,"conditions":197,"keywords":11,"overallStatus":143,"whyStopped":11,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":209},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage Change in Body Weight from Baseline",null,"From Baseline to Week 64",[14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,50,52,54,57,59,61,63,65,67,69,71,73,75,77,79,81,83,85,87,89,91,93,95,97],{"measure":15,"description":11,"timeFrame":12},"Proportion of Participants Achieving ≥ 5% Body Weight Loss from Baseline",{"measure":17,"description":11,"timeFrame":12},"Proportion of Participants Achieving ≥ 10% Body Weight Loss from Baseline",{"measure":19,"description":11,"timeFrame":12},"Proportion of Participants Achieving ≥ 15% Body Weight Loss from Baseline",{"measure":21,"description":11,"timeFrame":12},"Change from Baseline in Waist Circumference (cm)",{"measure":23,"description":11,"timeFrame":12},"Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)",{"measure":25,"description":11,"timeFrame":12},"Change from Baseline in Triglycerides",{"measure":27,"description":11,"timeFrame":12},"Change from Baseline in High-Density Lipoprotein (HDL) Cholesterol",{"measure":29,"description":11,"timeFrame":12},"Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQoL-Lite-CT) Physical Functioning Composite Score",{"measure":31,"description":11,"timeFrame":12},"Change from Baseline in IWQoL-Lite-CT Physical Functioning Composite Score in Participants with Poor Physical Functioning at Baseline (as defined by Patient Global Impression of Severity\u002FStatus [PGI-S])",{"measure":33,"description":11,"timeFrame":12},"Change from Baseline in Short Form (36) Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score",{"measure":35,"description":11,"timeFrame":12},"Change from Baseline in SF-36v2 Acute Form Physical Functioning Domain Score in Participants with Poor Physical Functioning at Baseline (as defined by PGI-S)",{"measure":37,"description":11,"timeFrame":12},"Change from Baseline in Mean Daily Food Craving Score",{"measure":39,"description":11,"timeFrame":12},"Change from Baseline in Mean Daily Peak Hunger Score",{"measure":41,"description":11,"timeFrame":12},"Change from Baseline in Body Mass Index (BMI) (kg\u002Fm²)",{"measure":43,"description":11,"timeFrame":12},"Change from Baseline in Body Weight (kg)",{"measure":45,"description":11,"timeFrame":12},"Change from Baseline in Waist-to-Hip Ratio",{"measure":47,"description":11,"timeFrame":12},"Change from Baseline in Waist-to-Height Ratio",{"measure":49,"description":11,"timeFrame":12},"Change from Baseline in Fasting Insulin",{"measure":51,"description":11,"timeFrame":12},"Change from Baseline in Fasting Glucose",{"measure":53,"description":11,"timeFrame":12},"Change from Baseline in Hemoglobin A1c (HbA1c)",{"measure":55,"description":11,"timeFrame":56},"Percentage of Participants with Type 2 Diabetes at Screening Achieving HbA1c of \u003C 5.7%","At Week 64",{"measure":58,"description":11,"timeFrame":56},"Percentage of Participants with Type 2 Diabetes at Screening Achieving HbA1c of \u003C 6.5%",{"measure":60,"description":11,"timeFrame":56},"Percentage of Participants with Type 2 Diabetes at Screening Achieving HbA1c of \u003C 7%",{"measure":62,"description":11,"timeFrame":56},"Percentage of Participants With Baseline Prediabetes Achieving HbA1c of \u003C 5.7%",{"measure":64,"description":11,"timeFrame":12},"Change from Baseline in Very-Low-Density Lipoprotein (VLDL) Cholesterol",{"measure":66,"description":11,"timeFrame":12},"Change from Baseline in Non-HDL Cholesterol",{"measure":68,"description":11,"timeFrame":12},"Change from Baseline in Total Cholesterol",{"measure":70,"description":11,"timeFrame":12},"Change from Baseline in Low-Density Lipoprotein (LDL) Cholesterol",{"measure":72,"description":11,"timeFrame":12},"Change from Baseline in Free Fatty Acids",{"measure":74,"description":11,"timeFrame":12},"Change from Baseline in Systolic Blood Pressure",{"measure":76,"description":11,"timeFrame":12},"Change from Baseline in Diastolic Blood Pressure",{"measure":78,"description":11,"timeFrame":12},"Change from Baseline in Health-Related Quality of Life (HRQoL) as assessed by SF-36v2 Acute Form Domain Scores and Component Summary Scores",{"measure":80,"description":11,"timeFrame":12},"Change from Baseline in HRQoL as assessed by IWQoL-Lite-CT Domain Scores and Total Score",{"measure":82,"description":11,"timeFrame":12},"Proportion of Participants with ≥ 14.6-Point Increase from Baseline in IWQoL-Lite-CT Physical Function Score",{"measure":84,"description":11,"timeFrame":12},"Proportion of Participants with ≥ 3.7-Point Increase from Baseline in SF36v2 Physical Functioning Score",{"measure":86,"description":11,"timeFrame":12},"Proportion of Participants with Baseline Poor Physical Functioning Achieving ≥ 14.6-Point Increase in IWQoL-Lite-CT Physical Functioning Score",{"measure":88,"description":11,"timeFrame":12},"Proportion of Participants with Baseline Poor Physical Functioning Achieving a ≥ 3.7-Point Increase in SF36v2 Physical Functioning Score",{"measure":90,"description":11,"timeFrame":12},"Change from Baseline in Mean Daily Average Hunger Score",{"measure":92,"description":11,"timeFrame":12},"Change from Baseline in Mean Daily Average Satiety Score",{"measure":94,"description":11,"timeFrame":12},"Change from Baseline in Mean Daily Average Appetite Score",{"measure":96,"description":11,"timeFrame":12},"Incidence and Severity of Adverse Events, with Severity Determined According to Mild\u002FModerate\u002FSevere Criteria",{"measure":98,"description":11,"timeFrame":12},"Percentage of Participants with Baseline Anti-Drug Antibodies (ADAs) and Treatment-Emergent ADAs Against Petrelintide",{"allocation":100,"interventionModel":101,"interventionModelDescription":11,"primaryPurpose":102,"observationalModel":11,"timePerspective":11,"maskingInfo":103},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":104,"maskingDescription":11,"whoMasked":105},"QUADRUPLE",[106,107,108,109],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[111,116],{"label":112,"type":113,"description":11,"interventionNames":114},"Petrelintide","EXPERIMENTAL",[115],"Combination Product: Petrelintide",{"label":117,"type":118,"description":11,"interventionNames":119},"Placebo","PLACEBO_COMPARATOR",[120],"Combination Product: Placebo",[122,129],{"type":123,"name":112,"description":124,"armGroupLabels":125,"otherNames":126},"COMBINATION_PRODUCT","Petrelintide will be administered subcutaneously (SC) using a drug-device combination product.",[112],[127,128],"RO7895515","ZP8396",{"type":123,"name":117,"description":130,"armGroupLabels":131,"otherNames":11},"Petrelintide-matching placebo will be administered SC using a drug-device combination product.",[117],[133,138],{"name":134,"role":135,"phone":136,"phoneExt":11,"email":137},"Reference Study ID Number: CC46446 https:\u002F\u002Fforpatients.roche.com\u002FNo attachments to email below.","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":139,"role":135,"phone":11,"phoneExt":11,"email":11},"Fastest Response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[141,155,165],{"facility":142,"status":143,"city":144,"state":145,"zip":146,"country":147,"countryCode":148,"cosmosGeoPoint":149,"geoPoint":154,"contacts":11},"Pinnacle Research Group","RECRUITING","Anniston","Alabama","36207","United States","US",{"type":150,"coordinates":151},"Point",[152,153],-85.83163,33.65983,{"lat":153,"lon":152},{"facility":156,"status":143,"city":157,"state":158,"zip":159,"country":147,"countryCode":148,"cosmosGeoPoint":160,"geoPoint":164,"contacts":11},"Institute for Metabolic Research Los Angeles","Los Angeles","California","90015",{"type":150,"coordinates":161},[162,163],-118.24368,34.05223,{"lat":163,"lon":162},{"facility":166,"status":143,"city":167,"state":168,"zip":169,"country":147,"countryCode":148,"cosmosGeoPoint":170,"geoPoint":174,"contacts":11},"Progressive Medical Research","Port Orange","Florida","32127",{"type":150,"coordinates":171},[172,173],-80.99561,29.13832,{"lat":173,"lon":172},{"type":176,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[178],{"name":179,"class":6},"Zealand Pharma","100657881","phase-3-a-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-petrelintide-in-participants-with-overweight-or-obesity-and-established-cardiovascular-disease-100657881",false,"NCT07843472","A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease","A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardiovascular Disease","ZUPREME-5","Inclusion Criteria:\n\n* Participants with BMI ≥ 27 kg\u002Fm² and established CVD\n* History of at least one self-reported unsuccessful dietary effort to lose body weight\n\nExclusion Criteria:\n\n* Known history of Type 1 diabetes mellitus\n* Current or previous treatment with petrelintide or any other amylin analog","ALL","40 Years",{"count":191,"type":192},2500,"ESTIMATED","INTERVENTIONAL",[195],"PHASE3","This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).",[198,199],"Obesity or Overweight","Cardiovascular Disease","2026-10-05",{"date":202,"type":203},"2026-10-07","ACTUAL",{"date":205,"type":203},"2026-09-30",{"date":207,"type":192},"2030-10-06",{"name":5,"class":6},3]